Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of JNJ-63723283 (cetrelimab) in Advanced Cancers
2023-506144-16-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of cetrelimab in Nonhematologic neoplasms, sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-limiting toxicities in Part 1, Overall response rate in Part 2 and 2 more. Planned start Jul 2024; status: authorised.
02
Drugs
cetrelimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-506144-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506144-16-00.